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It has been demonstrated that MSCs are able to migrate to the sites of injury and that they
have some distinct genetic profiles compared to BM-MSCs. The current review summaries
the basic knowledge of circulating MSCs and their potential clinical applications, such as mobi-
lizing the BM-MSCs into circulation for therapy. The application of MSCs to cure a broad spec-
trum of diseases is promising, such as spinal cord injury, cardiovascular repair, bone and
cartilage repair. The current review also discusses the issues of using of allogeneic MSCs for
clinical therapy.
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Mesenchymal stem cells (MSCs) are non-haematopoietic
cells which can be easily isolated from bone marrow and
other tissues, such as adipose, umbilical cord, and periph-
eral blood. The MSCs have a multipotent capacity toore) Pte Ltd. This is an open access article under the CC BY-NC-ND
2 L. Xu, G. Lidifferentiate into a variety of other cell types, including
osteoblasts, adipocytes, chondrocytes, myoblasts, and
neurons [1,2]. In response to stimuli, MSCs have the ability
of homing to the target tissue. Also, MSCs have been shown
to be immunosuppressive and anti-inflammatory; they do
not express major histocompatibility complex-II (MHC-II),
CD80, CD86, and CD40, and minimally express MHC-I on the
cell surface [1,3]. These characteristics have made MSCs a
promising cell source for tissue engineering.
Circulating MSCs, also called peripheral blood-derived
MSCs (PB-MSCs), were initially discovered as fibroblast-like
cells and were later confirmed by many investigators as
peripheral blood-borne colony-forming units [4,5]. Usually,
they exist at a very low level in healthy individuals, but
under some pathological conditions, the number of circu-
lating MSCs is greatly increased [6,7]. In 2007, we reviewed
some studies/knowledge about circulating MSCs and their
relationship with bone marrow-derived MSCs (BM-MSCs) [8].
In this current review, we give a brief summary of the
current studies about circulating MSCs and analyse
the clinical application of circulating MSCs in tissue
regeneration.
Biological characteristics of circulating MSCs
As there are no consistent defining characteristics of MSCs
among researchers, the International Society for Cellular
Therapy has proposed three criteria that have been
generally accepted to categorise progenitor cells as MSCs:
(1) adherence to plastic; (2) specific surface antigen
expression; and (3) multipotent differentiation potential.
Circulating MSCs also fulfil these requirements.
The frequency of BM-MSCs in humans under normal condi-
tions is very low, ranging from 1 in 104 to 1 in 105 bonemarrow
mononuclear cells (MNCs) [9]. Compared with BM-MSCs, the
frequency of circulating MSCs in humans is even lower, in the
orderof1 in108peripheral bloodMNCs [10]. Fernandezandco-
workers [11] successfully identifiedcellswith features ofMSCs
in growth-factor-mobilized peripheral blood cells from breast
cancer patients. The MSCs identified by Fernandez and co-
workers [11] expressed collagen I, collagen III, fibronectin,Figure 1 Surface markers of rat peripheral blood-derived mese
(BM-MSCs), as analysed by flow cytometry. Isotype controls are re
surface markers are represented in black. The PB-MSCs and BM-MSCD106,CD54, SH2,andSH3,butdidnotexpressantigensCD34,
CD45, and CD14. However, they did not find any stromal cells
in normal peripheral blood cells which were not mobilized by
growth factors. Three years later, Zvaifler and co-workers [12]
successfully identified mesenchymal precursor cells in the
blood of normal individuals, and these cells were referred to
as blood-derived mesenchymal precursor cells. These blood-
derived mesenchymal precursor cells also did not express
CD34, CD45, and CD14, but were positive for vimentin,
collagen I, bonemorphogenetic protein receptors IA (BMPR IA)
and BMPR IB. In the stromal cells obtained from mobilized
peripheral blood cells, two cell populations were observed;
fibroblast-like cells and some small round cells. Zvaifler and
co-workers [12] also observed that both fibroblast-like cells
and some large round cells exist in the predominant cells, and
they found that culture conditions are an important factor
which can modify the morphology of the progenitor cells.
Despite the difficulty in detection, to date, circulating
MSCs have been detected and isolated from various species,
such as guinea pig, mouse, rabbit, rat, and humans [8]. We
have successfully isolated and cultured PB-MSCs from adult
Sprague Dawley rats under normal conditions. The BM-MSCs
and PB-MSCs showed similar characteristics of cell prolif-
eration and multi-differentiation potentials. We compared
the expression of a set of surface markers, and found that
CD73 may be an important indicator to distinguish PB-MSCs
from BM-MSCs (as summarized in Fig. 1). PB-MSCs are also
plastic-adherent and have multi-differentiation potential.
They can be differentiated into adipocytes, chondrocytes,
and osteocytes under certain conditions, as proved by
previous publications and our unpublished study.
MSCs homing
The capacity of MSCs to home and migrate to the target
tissue is an important determinant for the clinical use of
MSCs. For example, for bone formation to occur, MSCs must
migrate to the bone surface, where they differentiate into
osteoblasts and deposit bone matrix. There is a prevailing
view that circulating MSCs engraft more rapidly than BM-
MSCs [13]. Although the mechanisms for MSCs homing/nchymal stem cells (PB-MSCs) and bone marrow-derived MSCs
presented in red, and the analysis with antibodies for cellular
Cs shared similar phenotypic CD markers.
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involved are not fully identified, a likely paradigm for MSCs
migration has already come into being. It is proposed that
the mechanism used for MSCs homing is similar to the well-
documented trafficking and homing of haematopoietic
stem cells to the bone marrow, and leukocytes into the
inflamed tissues [14,15]. Of course, there are some differ-
ences among them. For example, the MSCs do not express
ligands to endothelial selectins, such as P-selectin glyco-
protein ligand-1 (PSGL-1) or sialyl Lewis X carbohydrates, so
MSCs are not able to bind to chimeric constructs of the
endothelial selectins CD62E (E-selectin) and CD62P (P-
selectin).
Recently, the chemokine stromal cell-derived factor-1
(SDF1)/CXC chemokine receptor-4 (CXCR4) axis has been
recognized as controlling the migration of MSCs [16,17].
CXCR4, a 352 amino acid rhodopsin-like G-protein-coupled
receptor, binds with SDF1 and induces intracellular signal-
ling transduction through several divergent pathways which
are related to chemotaxis, cell survival, proliferation, and
gene transcription. Our previous study also showed that
CXCR4 was involved in MSCs homing and engraftment to
tumours, the migration potential of MSCs toward tumour
cells was enhanced with the upregulation of CXCR4 when
MSCs were exposed to tumour conditioned medium, and the
SDF1 inhibitor, AMD3100, could partly abolish the MSCs
migration toward tumour cells [18]. A big issue concerning
the SDF1/CXCR4 axis is that CXCR4 is usually absent on the
surface of MSCs culture-expanded in vitro [16,19,20]. To
overcome this problem, stimulating the expression of
CXCR4 is one of the strategies for enhancing the migration
capacity of MSCs [21e23].Figure 2 Schematic illustration of the migration of mesen-
chymal stem cells (MSCs) to the site of injury. MSCs reside in
the bone marrow until stimulated by alarm signals, such as
stromal cell-derived factor-1 (SDF1), vascular endothelial
growth factor A (VEGF-A), and fibroblast growth factor 2
(FGF-2) in the plasma.MSCs for tissue regeneration
The capacity of MSCs is outstanding, such as multi-
differentiation, immunosuppression, and immune privi-
lege. In addition, they do not have the ethical issues like
embryonic stem cells. These unique privileges make MSCs a
promising cell source for cytotherapy. There is accumu-
lating evidence that MSCs can be used to cure a broad
spectrum of diseases, such as spinal cord injury, cardio-
vascular repair, bone and cartilage repair.
For the use of MSCs in cardiovascular repair, it has been
demonstrated that systemically injected MSCs migrate to
the infarcted myocardium at various time points, and some
of the MSCs undergo differentiation to a cardiac phenotype,
whereas other cells participate in angiogenesis in the
infarcted area [24]. MSCs can survive very well in a xeno-
geneic environment while retaining their abilities. In
another study involving the autologous delivery of bone
marrow cells into the infarct border zone in patients who
had a myocardial infarction, all patients were alive and
well at 3e9 months after surgery, and 80% (5/6) of the
patients showed greatly improved infarct tissue perfusion;
70% (4/6) of the patients showed enhanced global left-
ventricular function [25].
Also, there are many examples of the application of
MSCs in the area of bone and cartilage repair. Quarto et al.
[26] reported that local delivery of bone marrow stem cells
combined with macroporous hydroxyapatite scaffoldsresults in substantial improvement in repairing large de-
fects in long bones. Similarly, Solchaga et al. [27] reported
the use of a combination of scaffold and bone marrow to
treat osteochondral defects in rabbits. The results indicate
that bone marrow loading appears to accelerate the first
stage of the repair process after 3 weeks. In a caprine
model of osteoarthritis, it has been demonstrated that local
delivery of MSCs to the injured joints can stimulate marked
regeneration of the medial meniscus, the implanted MSCs
can be detected in the newly formed tissues, and the
normally seen progressive destruction in this model is
retarded [28]. The effect of systemically injected MSCs on
fracture healing is evaluated in a mouse fracture healing
model; the results indicate that MSCs transplantation
significantly increases cartilage and bone content and im-
proves the fracture healing by improving the callus
biomechanical properties [29]. To treat femoral head ne-
crosis in rabbit models, intravenous transplantation of MSCs
has been proven to migrate directionally and survive in the
necrotic femoral heads without immunological rejection
[30].
Most of the studies were conducted using bone marrow-
or other tissue-derived MSCs. However, the application of
PB-MSCs is rarely reported. The main reason is that isola-
tion and culture of PB-MSCs is not as easy as other tissue
derived-MSCs. In 2006, our group demonstrated that PB-
MSCs could enhance bone regeneration in the rabbit ulna
critical-sized bone defect model [31].
Although the application of MSCs to cure a broad spec-
trum of diseases is promising, the efficacy still needs to be
improved, especially for the differentiation of MSCs into
specified functional cells in vivo. Many genes, chemicals,
and cytokines have been used to enhance the efficacy of
transplanted MSCs recently. For example, administration of
interleukin 6 has been found to enhance the ability of MSCs
to repair liver after CCl4-induced fibrosis in mice [32].
Systemically administrated MSCs transduced with BMP2 and
a4 integrin have been demonstrated to increase bone
density in a mouse model of osteopenia [33]. To manipulate
specific gene expression in MSCs that may enhance their
4 L. Xu, G. Lidifferentiation, proliferation, migration, and survival would
be the future research directions.Mobilization of MSCs
As mentioned, the characteristics of BM-MSCs and PB-MSCs
are similar. Although BM-MSCs can be isolated and cultured
very easily from bone marrow to fulfil the requirement of
clinical use, the process of isolating MSCs from patients is
complicated and painful. Compared with BM-MSCs, the
number of PB-MSCs is rarer in the blood and the isolation
method is not well defined. For clinical application, the PB-
MSCs seem to be more promising as long as we can find the
solutions to effectively isolate and culture them in vitro.
The general method used to isolate PB-MSCs is Ficoll-Paque,
which may affect the proliferation and survival of PB-MSCs,
and the components of the medium also need to be eval-
uated, such as supplements of some growth factors.Table 1 Summary of publications using allogeneic mesenchyma
Diseases/animal model Recipient species
Sjo¨gren syndrome Mouse, human MSCs suppresse
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activity in 34 (
Acute kidney injury Rat Reduce late re
animals.Circulating MSCs are present in the peripheral blood in
minimal concentrations under normal conditions. However,
their numbers significantly increase in the blood after
injury, such as bone fracture [34] and large acute burns
[35]. Also, the increase in circulating MSCs is seen in pa-
tients with some chronic diseases, such as osteoporosis
[36], breast cancer [11], and bone sarcomas [6]. It is
believed that these increased MSCs may be released from
the bone marrow. Our previous work has demonstrated
that some osteoblasts involved in fracture healing are sys-
temically mobilized and recruited to the fracture site from
remote bone marrow, rather than passively leaked into the
circulation and to the bone injury site [37]. How do MSCs in
the bone marrow know where and when injuries happen? It
is well known that various cytokines and a complex inter-
action of chemical alarm signals are released from the
injured tissues, and these alarm signals are sent to MSCs
through some pathways that have not yet been clearly
elucidated. For example, significant increases of SDF1,l stem cells (MSCs) in cell therapy applications.
Outcome Refs
d autoimmunity and restored salivary gland secretory
h mouse models and Sjo¨gren syndrome patients.
[47]
s are as safe and effective as autologous MSCs in
eft ventricular dysfunction due to ischaemic
y.
[46]
tation is safe and effective in patients with drug-
yositis or dermatomyositis.
[48]
netic protein 2 (BMP-2) engineered allogeneic MSCs
cal bone defects to the same degree as rats treated
ineered autologous MSCs.
[49]
in subsided from intermittent 10/10 to once/week
very of muscle, bowel and sexual function was noted,
crease in American spinal injury association (ASIA)
[50]
ifference was found between rabbits with
togenous MSCs and rabbits with transplanted
s either in the femur length, or in its valgus deformity.
[51]
ft after transplantation, differentiate to osteoblasts
fibroblasts, and produce clinical benefits.
[52]
farct size and prevent subsequent adverse cardiac [53]
urse was stabilized after the transplantation. [54]
tation resulted in the induction of clinical remission
nt in organ dysfunction in drug-resistant systemic
tosus patients. No transplantation-related adverse
rved.
[55]
analyses for arthroscopy, histology, and magnetic
ing revealed a better outcome in the MSCs-treated
[56]
administration of Fetal membrane-derived MSCs
uated myocardial dysfunction and inflammation, and
ediated immune response was attenuated.
[57]
ation resulted in an improvement in the skin of two
he observed clinical benefit lasted for 4 months.
[58]
ical and morphological indices of inflammatory
72.7%) patients.
[59]
nal fibrosis and loss of renal function in surviving [60]
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Fibroblast growth factor 2 (FGF-2) in the plasma have been
detected in patients with ST elevation acute myocardial
infarction [38]. When MSCs in the bone marrow received
these alarm signals, some of these can be mobilized into
the bloodstream depending on how serious the injuries are,
as illustrated in Fig. 2.
Administration of some cytokines can mimic the alarm
signals and mobilize MSCs into blood. This can increase the
number of MSCs in the blood, and makes the isolation of
circulating MSCs possible. Recently, researchers have found
that granulocyte-colony stimulating factor (G-CSF), a
cytokine that contributes to haematopoietic progenitor
cells and endothelial progenitor cells mobilization [39e41],
can also be used to mobilize MSCs [42]. By using fibrin
microbeads that can bind matrix-dependent cells, Kassis
et al. [42] have isolated PB-MSCs from adult healthy human
donors treated with G-CSF. Although they only get PB-MSCs
from eight out of 11 samples, and the yield is lower than
bone marrow, they made a big progress compared with the
conventional method. In 2011, Iwasaki et al. [43] reported
that the hepatocyte growth factor could also stimulate the
migration of circulating mesoangioblasts (circulating
mesenchymal cells that co-express endothelial makers).Other issues of circulating MSCs: autologous
versus allogeneic transplantation
Studies on circulating MSCs are rare in the literature. To our
best understanding, circulating MSCs are a special subset of
MSCs that are found in the circulation. However, their
origin may be from bone marrow and other pools of MSCs in
the body, and their release is tightly controlled by systemic
and local factors (such as inflammatory cytokines, hor-
mones, and growth factors). Stem cell homing refers to the
inherent ability of stem cells to navigate toward a specific
location (such as injury, inflammation, or infection) through
unfamiliar areas. Stem cell mobilization means stem cells
assemble and move toward specific stimuli or signals
(directional movement), whereas cell migration is the
inherent ability of cell movement and the migration may be
directional or random. There are debates on the use of
autologous and allogeneic MSCs through local and systemic
administration for cell therapy applications. When admin-
istrated systemically, MSCs may share certain characters
with circulating MSCs. Because circulating MSCs are difficult
to obtain from the blood, currently, our knowledge about
them comes largely from studies of BM-MSCs.
Autologous MSCs transplantation means that the patient
receives their own MSCs, with no risk of graft-versus-host
disease. The disadvantage of autologous MSCs trans-
plantation is that a longer time is needed (several days or
weeks) for MSCs cell preparation, and the treatment win-
dow may be missed. In addition, sometimes the quality of
autologous MSCs cannot be guaranteed in patients with
comorbidities or advanced age [44,45].
Allogeneic MSCs transplantation is a procedure in which
the patient receives MSCs from other donors. Allogeneic
MSCs can be used as an “off-the-shelf” therapeutic agent,
thus avoiding the painful bone marrow aspiration and cul-
ture delays prior to treatment. The potential risk fromusing allogeneic MSCs is rejection. However, so far, there
have been no reports of serious adverse side effects
following allogeneic systemic and local administration of
MSCs, including immunological complications in animals
and human studies reported. There is increasing evidence
to prove that MSCs are immunosuppressive cells and that
allogeneic MSCs may be used with similar therapeutic effi-
cacy to autologous MSCs. The study carried out by Hare
et al. [46] demonstrated that allogeneic MSCs are as safe
and as effective as autologous MSCs in patients with
ischaemic cardiomyopathy. They also found that allogeneic
MSCs did not stimulate significant donor-specific alloim-
mune reactions. So, allogeneic MSCs transplantation seems
to be more promising, as it ensures that patients can get
treatment at the best time with well-prepared allogeneic
MSCs. Publications showing administration of allogeneic
MSCs for curing various diseases are summarized in Table 1.
To date, no standard procedure for therapeutic MSC
administration has been agreed on, which remains one of
the critical issues for the clinical application of MSCs. For
instance, the following questions still have open answers.
How many MSCs should be used for patients with different
diseases? When is the best time for MSC application? What
kind of MSCs is most suitable? Which routine of adminis-
tration and how often should MSCs be given (once/week or
twice/week)? All these issues are valid ones and should be
addressed properly through carefully designed animal and
clinical trials before large-scale clinical applications of
MSCs can be trialled and accepted in patients with certain
disease conditions.
Conclusion
In conclusion, MSCs play an important role in the regener-
ative processes of many tissues. Circulating MSCs is a new
cell source for tissue regeneration and tissue engineering.
The implication of circulating MSCs in diseases is more
promising, although many questions remain to be clarified,
such as MSC mobilization from the bone marrow, homing
mechanisms to specific tissues, and functional roles in vivo.
In clinical practice, the use of allogeneic MSCs is more
practical and may become the main cell source for clinical
cell therapy. There are still many questions needing an-
swers, and these answers have to come from carefully
designed animal and clinical trials.
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